Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its stock increase by 4% after the company announced that the FDA had approved ...

Venofer was approved in the U.S. in 2000. It was developed by Vifor Pharma, which is now part of CSL Ltd. American Regent, a unit of Daiichi Sankyo, manufactures and sells it in the U.S. under a ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to ...

Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) jumped 10.4% in the morning session after the company announced it received U.S. Food and Drug Administration (FDA) approval for ...

Investing.com -- Amphastar Pharmaceuticals (NASDAQ: AMPH) stock gained 4% after the company announced FDA approval for its generic version of iron sucrose injection, a treatment for iron deficiency ...

Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) in Q2 CY2025, with sales falling 4.4% year on year to $174.4 ...

Amphastar Pharmaceuticals Inc (AMPH) reports robust vaccine sales and strategic growth plans, despite facing challenges from increased competition and margin pressures.

Amphastar is undervalued (~71% upside), but lacks an economic moat and faces modest growth, so I favor a cautious gradual ...

On a per-share basis, the Rancho Cucamonga, California-based company said it had profit of 64 cents. Earnings, adjusted for one-time gains and costs, were 85 cents per share. The results exceeded Wall ...

According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chro ...